Thrombotic Thrombocytopenic Purpura, Acquired
Conditions
Brief summary
The aim of the study is to evaluate the efficacy of a personalized caplacizumab regimen based on ADAMTS13 activity monitoring in adult acquired thrombotic thrombocytopenic purpura (aTTP): This study is a phase II, prospective, multicenter non-inferiority single-arm study.
Detailed description
ADAMTS13 activity will be evaluated on day 7 after the end of daily PE and every 7 days until ADAMTS13 activity ≥ 20% is reached. In case of persistent severe ADAMTS13 deficiency (≤ 20%), caplacizumab administration could be extended for a maximum of 58 days after the end of the daily PE period and should be accompanied by an adjusted immunosuppressive therapy as needed. This duration is in accordance with the HERCULES study protocol and its SmPC.
Interventions
DRUGCaplacizumab
Analyse of ADAMTS13 activity in patients with aTTP treated with Caplacizumab in order to help adapting the treatment with caplacizumab in TTP patients
Sponsors
University Hospital, Rouen
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Experimental, prospective, non-comparative, multicentric national study
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* Adult patients ≥ 18 years; * Clinical diagnosis of aTTP based on standard clinical and laboratory criteria (French Score ≥ 2): i.e., thrombotic microangiopathy syndrome with platelet count ≤ 30 G/L and serum creatinine ≤ 200 μmol/L; severe ADAMTS13 deficiency is not a requirement for inclusion of patients with a French score of 2 \[31\]; * Patient having read and understood the information letter and signed the Informed Consent Form. If the patient is unable to express his consent, the consent will be signed by his representative ((1) the trusted person, or failing that, (2) a family member, or (3) a close relative of the person concerned). In this case, consent to continue the study will subsequently be requested from the patient (article L1122-1-1 of the CSP); * Patient affiliated with, or beneficiary of a social security (national health insurance) plan; * For women: * Women of childbearing potential : * Effective contraception according to WHO definition (estrogen-progestin or intrauterine device or tubal ligation) since at least 1 month and; * Negative blood pregnancy test; * Women surgically sterile (absence of ovaries and/or uterus); * Postmenopausal women (non-medically induced amenorrhea for at least 12 months prior to the inclusion visit).
Exclusion criteria
* Platelet count \> 100 G/L; * Patients with a French score \< 2 (a serum creatinine level \> 200 μmol/L +/- associated with a platelet count \> 30 G/L), in order to exclude possible cases of atypical hemolytic uremic syndrome; * Known other causes of cytopenias and/or organ failure including but not limited to: uncontrolled cancer, chemotherapy, transplant, drugs, HIV at AIDS stage; * Pregnant women (positive result from a blood pregnancy test) or patients with an imminent project of pregnancy; breastfeeding women (due to lack of pharmacological data for caplacizumab during pregnancy and breastfeeding); * Congenital TTP; * Clinically significant active bleeding or high risk of bleeding (excluding thrombocytopenia); * Chronic treatment with anticoagulant that cannot be interrupted safely, including but not limited to: vitamin K antagonists, direct oral anticoagulant, low molecular weight heparin or heparin; * Malignant hypertension; * Contra-indication to CABLIVI 10 mg powder and solvent for solution for injection: hypersensitivity to caplacizumab or to any of the excipients; * Contra-indication to PE treatment; * Contra-indication to corticosteroid (= ((methyl)prednisone or (methyl)prednisolone)) or excipients; * Contra-indication to rituximab or excipients and to its premedication; * Person deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision); * Participation in another drug interventional clinical trial within 30 days prior to inclusion and during the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the feasibility of a personalized caplacizumab regimen in aTTP based on ADAMTS13 activity monitoring assessed by a composite criteria including mortality, refractoriness and/or exacerbation at 30 days post-PE treatment | 30 days post-PE treatment | composite endpoint defined by the occurrence of at least one the following events during the 30 days post-PE treatment: death, refractoriness or exacerbation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate the Quality of life | Day 90 post-PE treatment | Quality of life based on global post-traumatic score (PCL-S SCALE) at baseline, D90 post-PE treatment |
| Response to treatment (platelet count recovery) | 30 days post-PE treatment | to platelet count recovery (as defined by a platelet count ≥ 150 G/L with a subsequent interruption of daily PE within 5 days) |
| Durable remission achievement | 90 days post-PE treatment | Occurrence of durable remission achievement (platelet count ≥ 150 G/L for ≥ 30 consecutive days following PE interruption); |
| Mortality at D90 post-PE treatment | 90 days post-PE treatment | Occurrence of death within 90 days post-PE treatment |
| Refractoriness at D30 post-PE treatment | Day 30 post-PE treatment | Occurrence of refractoriness at D30 post-PE treatment; |
| Exacerbation at D30 post-PE treatment | Day 30 post-PE treatment | Occurrence of exacerbations at D30 post-PE treatment |
| Duration of plasma exchange (PE) treatment and the associated plasma volumes | 30 days | Duration of daily PE with the corresponding plasma volume |
| Duration of plasma exchange (PE) treatment and the associated plasma | 30 days | Total number of PE and the corresponding plasma volume during the full study drug treatment period |
| Evaluate the cost of the strategy | Day 90 post-PE treatment | Costs of the patients' management (Direct hospital medical expenses, Suppléments, direct costs of home care, caplacizumab injections, rehospitalizations) of patients treated with the regimen according to the study |
| To perform a safety analysis | 90 days post-PE treatment | Occurrence of AE and SAE during the study |
| Occurrence of neurological sequelae treatment | Day 90 post-PE treatment | Neurological assessment based on Rankin score |
| Occurrence of cognitive sequelae treatment | Day 90 post-PE treatment | Cognitive assessment based on MMS score |
Countries
France, Martinique
Outcome results
None listed